Bispecific Antibodies Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others), By Region & Competition, 2020-2030F

February 2025 | 180 pages | ID: BF2955413FF2EN
TechSci Research

Abstracts

Global Bispecific Antibodies Market was valued at USD 6.80 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 9.40% through 2030. The global bispecific antibodies market has been witnessing significant growth and innovation in the biopharmaceutical industry. Bispecific antibodies are a class of therapeutic proteins designed to simultaneously target two different antigens, providing a unique approach to treating various diseases, including cancer and autoimmune disorders.

Key Market Drivers

Rising Prevalence of Cancer and Autoimmune Diseases

The global bispecific antibodies (BsAbs) market is experiencing rapid expansion, primarily driven by the increasing incidence of cancer and autoimmune diseases worldwide. This trend is significantly boosting the demand for innovative, targeted biologics, positioning bispecific antibodies as a key therapeutic solution. In 2022, global cancer statistics revealed significant healthcare and economic challenges, with approximately 20 million new cancer cases diagnosed and 9.7 million cancer-related deaths recorded worldwide. The prevalence of cancer survivors within five years of diagnosis reached 53.5 million, underscoring the growing burden on healthcare systems to provide long-term care and support. Epidemiological data indicates that 1 in 5 individuals will develop cancer during their lifetime, with gender-specific mortality rates highlighting a higher risk among men (1 in 9) compared to women (1 in 12). These figures emphasize the critical need for innovative therapeutic solutions, early detection strategies, and scalable treatment options to address the rising global cancer burden. This rise is attributed to aging populations, lifestyle changes, and environmental factors. The growing cancer burden is increasing demand for advanced, highly effective therapies, which is propelling the adoption of bispecific antibodies in oncology. Unlike traditional monoclonal antibodies (mAbs), bispecific antibodies can simultaneously bind to two different antigens, enhancing tumor cell killing while reducing immune evasion. BsAbs can recruit and activate T cells or NK cells to attack tumor cells, offering a powerful alternative to standard chemotherapy and single-target biologics. Many cancer therapies face resistance over time, but BsAbs help overcome resistance mechanisms by targeting multiple pathways. BsAbs provide a more accessible and cost-effective option compared to personalized CAR-T therapies, which require complex manufacturing processes.

Key Market Challenges

Complex Design and Manufacturing

One of the primary challenges in the bispecific antibodies market is the complexity of their design and manufacturing processes. Creating bispecific antibodies that can simultaneously bind to two distinct molecules or cells requires precise engineering. The intricacies of their structure can lead to manufacturing challenges, impacting scalability, production costs, and consistency in quality.

Key Market Players

• Amgen Inc
• F. Hoffmann-La Roche Ltd
• Genentech Inc
• Akeso Inc
• Janssen (Johnson & Johnson Private Limited)
• Taisho Pharmaceutical Co Ltd
• Immunocore Ltd

Report Scope:

In this report, the Global Bispecific Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Bispecific Antibodies Market, By Indication:
• Cancer
• Inflammatory & Autoimmune Disorders
• Others
• Bispecific Antibodies Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bispecific Antibodies Market.

Available Customizations:

Global Bispecific Antibodies market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL BISPECIFIC ANTIBODIES MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
  5.2.2. By Region
  5.2.3. By Company (2024)
5.3. Product Market Map
  5.3.1. By Indication
  5.3.2. By Region

6. NORTH AMERICA BISPECIFIC ANTIBODIES MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
  6.2.2. By Country
6.3. North America: Country Analysis
  6.3.1. United States Bispecific Antibodies Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Indication
  6.3.2. Canada Bispecific Antibodies Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Indication
  6.3.3. Mexico Bispecific Antibodies Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Indication

7. EUROPE BISPECIFIC ANTIBODIES MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
  7.2.2. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Bispecific Antibodies Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Indication
  7.3.2. United Kingdom Bispecific Antibodies Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Indication
  7.3.3. France Bispecific Antibodies Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Indication
  7.3.4. Italy Bispecific Antibodies Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Indication
  7.3.5. Spain Bispecific Antibodies Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Indication

8. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
  8.2.2. By Country
8.3. Asia-Pacific: Country Analysis
  8.3.1. China Bispecific Antibodies Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Indication
  8.3.2. Japan Bispecific Antibodies Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Indication
  8.3.3. India Bispecific Antibodies Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Indication
  8.3.4. Australia Bispecific Antibodies Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Indication
  8.3.5. South Korea Bispecific Antibodies Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Indication

9. SOUTH AMERICA BISPECIFIC ANTIBODIES MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
  9.2.2. By Country
9.3. South America: Country Analysis
  9.3.1. Brazil Bispecific Antibodies Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Indication
  9.3.2. Argentina Bispecific Antibodies Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Indication
  9.3.3. Colombia Bispecific Antibodies Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Indication

10. MIDDLE EAST AND AFRICA BISPECIFIC ANTIBODIES MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
  10.2.2. By Country
10.3. MEA: Country Analysis
  10.3.1. South Africa Bispecific Antibodies Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Indication
  10.3.2. Saudi Arabia Bispecific Antibodies Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Indication
  10.3.3. UAE Bispecific Antibodies Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Indication
  10.3.4. Kuwait Bispecific Antibodies Market Outlook
    10.3.4.1. Market Size & Forecast
      10.3.4.1.1. By Value
    10.3.4.2. Market Share & Forecast
      10.3.4.2.1. By Indication

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. PORTER’S FIVE FORCES ANALYSIS

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. COMPETITIVE LANDSCAPE

14.1. Amgen Inc
  14.1.1. Business Overview
  14.1.2. Product & Service Offerings
  14.1.3. Recent Developments
  14.1.4. Financials (If Listed)
  14.1.5. Key Personnel
  14.1.6. SWOT Analysis
14.2. F. Hoffmann-La Roche Ltd
14.3. Genentech Inc
14.4. Akeso Inc
14.5. Janssen (Johnson & Johnson Private Limited)
14.6. Taisho Pharmaceutical Co Ltd
14.7. Immunocore Ltd

15. STRATEGIC RECOMMENDATIONS

16. ABOUT US & DISCLAIMER